Figure 2From: A randomized, double blind, placebo and active comparator controlled pilot study of UP446, a novel dual pathway inhibitor anti-inflammatory agent of botanical origin Change in WOMAC Stiffness Scores/100 by Visit and Study Group. UP446 250 mgs/day and UP446 500 mgs/day groups had consistently statistical significant changes from baseline during the study.Back to article page